Shares of Checkpoint Therapeutics Inc. (CKPT) reached a 52-week high of $4.33 during intraday trading yesterday, as the company gears up for a key regulatory catalyst in the coming weeks.
The company's lead investigational product Cosibelimab, an anti-programmed death ligand-1 ("PD-L1") antibody, is under FDA review, with a decision due on December 28, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com